| |||||||||||||||
| Rating | Health Concerns |
|---|---|
![]() |
Congestive heart failure (propionyl-L-carnitine) Intermittent claudication (propionyl-L-carnitine) |
![]() |
Anaemia (for thallasaemia) Attention deficit–hyperactivity disorder Chronic obstructive pulmonary disease (COPD) Intermittent claudication (L-carnitine) Sprains and strains (for preventing exercise-related muscle injury) |
![]() |
Athletic performance (for ultra-endurance only) Beta thallasaemia major Cardiomyopathy (only for children with inherited cardiomyopathy) Chemotherapy-induced fatigue |
Reliable and relatively consistent scientific data showing a substantial health benefit. Contradictory, insufficient, or preliminary
studies suggesting a health benefit or minimal health benefit. For an herb, supported by traditional use but
minimal or no scientific evidence. For a supplement, little scientific support and/or minimal
health benefit. | |
Carnitine deficiencies are rare, even in strict vegetarians, because the body produces carnitine relatively easily.
Rare genetic diseases can cause a carnitine deficiency. Also, deficiencies are occasionally associated with other diseases, such as diabetes and cirrhosis.13 14 Among people with diabetes, carnitine deficiency is more likely to be found in persons experiencing complications of diabetes (such as retinopathy, hyperlipidaemia, or neuropathy), suggesting that carnitine deficiency may play a role in the development of these complications.15 A carnitine deficiency can also result from oxygen deprivation which can occur in some heart conditions. In Italy, L-carnitine is prescribed for heart failure, heart arrhythmias, angina, and lack of oxygen to the heart.16
Most people do not need carnitine supplements. For therapeutic use, typical amounts are 1–3 grams per day.
It remains unclear whether the propionyl-L-carnitine form of carnitine used in congestive heart failure research has greater benefits than the L-carnitine form, since limited research in both animals and humans with the more common L-carnitine has also shown very promising effects.17
L-carnitine has not been consistently linked with any toxicity.
The body needs lysine, methionine, vitamin C, iron, niacin, and vitamin B6 to produce carnitine.
Are there any drug
interactions?
Certain medicines may interact with L-carnitine. Refer to drug interactions for a list of those medicines.
1. Giovannini M, Agostoni C, Salari PC. Is carnitine essential in children? J Int Med Res 1991;19:88-102.
2. Digiesi V, Palchetti R, Cantini F. The benefits of L-carnitine in essential arterial hypertension. Minerva Med 1989;80:227-31.
3. Mancini M, Rengo F, Lingetti M, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung 1992;42:1101-4.
4. Anand I, Chandrashenkhan Y, De Giuli F, et al. Acute and chronic effect of propionyl-L-carnitine on the hemodynamics, exercise capacity and hormones of patients with congestive heart failure. Cardiovasc Drugs Ther 1998;12:291-9.
5. Giamberardino MA, Dragani L, Valente R, et al. Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort. Int J Sports Med 1996;17:320-4.
6. Green RE, Levine AM, Gunning MJ. The effect of L-carnitine supplementation on lean body mass in male amateur body builders. J Am Diet Assoc 1997;(suppl):A-72.
7. Murray MT. The many benefits of carnitine. Am J Natural Med 1996;3:6-14 [review].
8. Columbani P, Wenk C, Kunz I, et al. Effect of L-carnitine supplementation on physical performance and energy metabolism of endurance-trained athletes: a double blind crossover field study. Eur J Appl Physiol 1996;73:434-9.
9. Dal Negro R, Pomari G, Zoccatelli O, Turco P. L-carnitine and rehabilitative respiratory physiokinesitherapy: metabolic and ventilatory response in chronic respiratory insufficiency. Int J Clin Pharmacol Ther Toxicol 1986;24:453-6.
10. Dal Negro R, Turco P, Pomari C, De Conti F. Effects of L-carnitine on physical performance in chronic respiratory insufficiency. Int J Clin Pharmacol Ther Toxicol 1988;26:269-72.
11. Beers MH, Berkow R (eds). The Merck Manual of Diagnosis and Therapy, 17th ed. Whitehouse Station, NJ: Merck and Co., Inc, 1999, 881-3.
12. Yesilipek MA, Hazar V, Yegin O. L-Carnitine treatment in beta thalassemia major. Acta Haematol 1998;100:162-3.
13. Dipalma JR. Carnitine deficiency. Am Fam Physician 1988;38:243–51.
14. Kendler BS. Carnitine: an overview of its role in preventive medicine. Prev Med 1986;15:373–90.
15. Tamamogullari N, Silig Y, Icagasioglu S, Atalay A. Carnitine deficiency in diabetes mellitus complications. J Diabetes Complications 1999;13:251–3.
16. Del Favero A. Carnitine and gangliosides. Lancet 1988;2:337 [letter].
17. Kobayashi A, Masumura Y, Yamazaki N. L-carnitine treatment for congestive heart failure—experimental and clinical study. Jpn Circ J 1992;56:86–94.
| |||||||